Home / Peptides
Semaglutide — weight loss

Semaglutide

Semaglutide

Also called: Ozempic, Rybelsus, Wegovy

By The Health Stacks Research TeamUpdated July 28, 2026

Semaglutide is a special medicine that acts like a natural hormone in the body to help control blood sugar and weight. Studies show it can also help the heart and liver work better.While semaglutide helps many people, it does not work for every health issue.

A long-acting GLP-1 receptor agonist. Mimics human glucagon-like peptide-1 to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management). Semisynthetic GLP-1 analog with a C18 fatty-acid side chain enabling albumin binding and extended half-life.

ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. Medium confidence40–59 — backed by moderate-quality sources. Worth a closer look at the individual citations.
Where to Source Semaglutide
Tested purity COA available Fast shipping

What Semaglutide Helps With

The benefits people report — backed by research.

Glycemic & metabolic (172)

Improves blood glucose control in type 2 diabetes 90/100· 16 srcHelps regulate blood sugar 95/100· 13 srcBoosts blood flow to injuries 90/100· 13 srcGlycemic control 95/100· 9 srcTreatment of Type 2 Diabetes 90/100· 9 srcLowers HbA1c in adults with type 2 diabetes 90/100· 9 srcImproves glycemic control in type 2 diabetes 95/100· 7 srcType 2 Diabetes Management 95/100· 4 srcLow risk of hypoglycemia 90/100· 3 srcLowers blood glucose levels 90/100· 3 srcLowers HbA1c levels by 1.2 to 1.8 percentage points 90/100· 3 srcGlycaemic control in Type 2 Diabetes 95/100· 2 srcManagement of type 2 diabetes 90/100· 2 srcSuppression of glucagon secretion 90/100· 2 srcReduction in HbA1c 90/100· 2 srcReduces risk of heart attack, stroke, or death in high-risk diabetes patients 90/100· 2 srcLowers blood glucose levels in type 2 diabetes 90/100· 2 srcImproves glycemic control in adults with type 2 diabetes 90/100· 2 srcReduced glucagon production 72/100· 2 srcReduction in Glycated Hemoglobin 95/100Achieving HbA1c <7.0% 95/100Reduction of progression to diabetes 95/100Decrease in blood glucose levels and glycated hemoglobin 95/100Inhibition of glucagon release 95/100Protection of β-cell function 95/100Absence of severe hypoglycemia 95/100Reduces progression to diabetes 95/100Lowers glucose levels 95/100Glycosylated hemoglobin A1c reduction 95/100Blood glucose lowering 95/100Renal protection 95/100Glucagon promotes net hepatic glycogen repletion following meal ingestion 95/10024% reduction in kidney disease progression in type 2 diabetes 95/100HbA1c reduction up to 2.07% and superior glycemic control vs placebo in type 2 diabetes 95/100HbA1c Reduction in Type 2 Diabetes 95/100Improving glucose regulation in diabetes 95/100GLP-1 receptor agonism for the treatment of type 2 diabetes 95/100Effective regulation of glucose metabolism in type 2 diabetes mellitus 95/10073% reduction in progression to diabetes 95/100Reduced risk of major kidney-related events by 24% in adults with CKD and type 2 diabetes 95/100Supports liver health 95/100Superior glycaemic control for semaglutide vs liraglutide 95/100HbA1c Reduction 95/100Improved composite glycemic outcome 95/100Reduction in A1C 95/100Improved Time in Tight Range 95/100Glycaemic improvement 95/100Glycemic Regulation 95/100Blood glucose regulation 95/100Lowered average A1c by 1% 95/100Lowered A1c by 2.1% 95/100Lowered A1c by 1.9% 95/100Improved glycemic control and HbA1c reduction 95/100Improvements in cardiometabolic risk factors 93/10073% relative reduction in progression to diabetes : 3.5% semaglutide vs 12% placebo 90/100Improved glycaemic control in adults with type 2 diabetes 90/100Improvements in waist size, cholesterol, and triglycerides 90/100Diabetes Management 90/100Treatment of Type 2 Diabetes Mellitus 90/100Treatment of Diabetes Insipidus 90/100Glycaemic control 90/100Treatment of diabetes 90/100Control of blood glucose levels in adults with type 2 diabetes 90/100Treatment of patients with type 2 diabetes mellitus 90/100Reversion of prediabetes to normoglycemia 90/100Blood glucose control without hypoglycemia 90/100Improvement of glycemic control in adults with type 2 diabetes mellitus 90/100Lowers blood glucose levels in adults with type 2 diabetes 90/100Reduces occurrence of serious health complications in high-risk diabetes patients 90/100Lowers HbA1c significantly in type 2 diabetes patients 90/100Reversion from prediabetes to normoglycemia 90/100GLP-1 analogs and derivatives for treating diabetes mellitus 90/100GLP-1 receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus 90/100Treatment of type 2 diabetes and glucose homeostasis management 90/100Glucagon-like peptide-1 receptor agonist 90/100Can lower A1C levels to under 7% 90/100Demonstrated effectiveness at treating type 2 diabetes 90/100Improves glycemic control in patients with type 2 diabetes mellitus 90/100Reducing the chance of worsening kidney problems in people with diabetes and chronic kidney disease 90/100Reduces risk of worsening kidney disease and kidney failure in type 2 diabetes with chronic kidney disease 90/100GLP-1 receptor agonists are legally approved peptide drugs for human use 90/100Pharmaceutical equivalence to Ozempic 90/100GLP-1 Medication Class for Metabolic Management 90/100GLP-1 receptor agonists class demonstrates HbA1c reductions of approximately 1.0–1.8% from baseline 90/100A1C reduction of 1.0-1.8% in adults with type 2 diabetes 90/100Lower rates of new or worsening kidney disease in patients with type 2 diabetes and heart disease 90/100GLP-1 receptor agonists as first-line therapy for Type 2 diabetes 90/100SGLT-2 inhibitors protect the heart and kidneys 90/100GLP-1s indicated for type 2 diabetes management 90/100Reduces the risk of heart attacks and stroke in adults with type 2 diabetes and heart disease 90/100Prevents kidney disease progression, kidney failure, and heart-related death in adults with type 2 diabetes and CKD 90/100Improvement of glycemic control as an adjunct to diet and exercise among adults with type 2 diabetes 90/100GLP-1 receptor agonist activity for metabolic regulation 90/100Lowers the risk of worsening kidney disease in people with Type 2 diabetes and kidney disease 90/100Active renal benefit in diabetic kidney disease 90/100Inhibits glucagon secretion 90/100Low Intrinsic Risk of Hypoglycemia 90/100Normalises blood glucose more frequently than lifestyle measures alone in non-diabetic hyperglycaemia 90/100Improved HbA1c 90/100Reduction in fasting glucose 90/100Improvement in lipid profile 90/100Improvement in A1C levels and normoglycemia achievement 90/100GLP-1 receptor agonist 90/100Glycemic control via GLP-1 receptor agonism 90/100Superior HbA1c reduction compared to Dulaglutide 90/100Once-weekly dosing capability 90/100Extended Half-life via Albumin Binding 90/100DPP-4 Resistance 90/100Reduces risk of heart attack, stroke, and death in Type 2 Diabetes 90/100Combination SGLT2 inhibitor and GLP-1 therapy reduces all-cause mortality 88/100Semaglutide provides risk reduction for adverse kidney outcomes independently of SGLT2 inhibitor use 88/100Protection of beta-cell function 85/100Cardiometabolic improvements including fasting glucose, A1c, and systolic blood pressure 85/100Prevention of type 2 diabetes progression in patients with prediabetes 85/100Conversion to normoglycemia in prediabetic patients 85/100A1c reduction 85/100Diabetes risk reduction 85/100Reduced risk of progressing to type 2 diabetes 85/100Reduced risk of developing dementia in Type 2 Diabetes patients 85/100Lower glycated hemoglobin levels sustained through 2 years 85/100Lower glycated hemoglobin levels sustained through the first 2 years 85/100Teplizumab delays the onset of type 1 diabetes in high-risk individuals 85/100Lower fracture risk in adults with type 2 diabetes 85/100Slowed progression of kidney disease in people with type 2 diabetes 85/100Renoprotection in Diabetic Nephropathy 85/100Improved metabolic markers 85/100GLP-1 release amplification 85/100Suppression of glucagon release 85/100GIP receptor activation 85/100GLP-1 receptor activation 85/100Improvements in A1c, triglycerides, and total cholesterol 80/100Management of dyslipidaemia and lipid metabolism diseases 80/100No increased risk for overall eye disorders or diabetic retinopathy 80/100Dual protracting moiety extends GLP-1 analogue half-life via C20/C22 diacid conjugation 80/100Dietary fibers can boost endogenous GLP-1 secretion modestly 80/100Enhanced chemical stability of cagrilintide and semaglutide 75/100Enhanced absorption of GLP-1 agonist 75/100Demonstrated fat reduction without affecting IGF-1 or glucose levels 75/100Accelerated absorption of GLP-1 agonist within 15-30 minutes after oral administration 75/100Increased exposure of GLP-1 agonists when compositions are prepared with a hydrotrope 75/100Diabetes treatment 72/100Activation of the GLP-1 receptor 72/100Enhanced Bioavailability via SNAC 72/100Reduction in serum triglycerides 72/100Improved oral bioavailability 72/100GLP-1 receptor agonists for type 2 diabetes 72/100Cost-effective access to GLP-1 therapy during drug shortages 72/100GLP-1 receptor agonists are legal, approved drugs for human use 72/100GLP-1 receptor agonist for type 2 diabetes treatment 72/100GLP-1 Peptides for Diabetes Management 72/100GLP-1 peptides effective for diabetes management 72/100GLP-1 peptides drive significant metabolic improvement 72/100Cost-effective alternative for GLP-1 therapy during drug shortages 72/100SGLT2 inhibitors offer heart and kidney benefits 72/100GLP-1 receptor agonists intended for individual patient needs when FDA-approved medications are unavailable 72/100Plozasiran lowers triglycerides in familial chylomicronemia syndrome 72/100Provides superb glycemic control in diabetes 72/100GLP-1 receptor agonists are effective for diabetes management 72/100Dual GLP-1 + GIP receptor agonism targets two hormones for enhanced glucose control 72/100Improves the way your body responds to sugars 72/100Low-carb diets lower blood glucose 72/100Highly effective for diabetes management 72/100Improved blood glucose control 72/100Dual hormone targeting for enhanced metabolic regulation 72/100Bypasses first-pass metabolism 72/100Extended half-life of roughly 7 days enabling weekly dosing 72/100Improvement in glucose control 72/100Low risk of hypoglycaemia 72/100Beta cell preservation 72/100Pa496h and Pa496m improve mitochondrial dynamics and lower elevated blood glucose in mouse models and human cell cultures 70/100Management of Type 2 Diabetes and hyperphagia in pediatric patients 70/100GLP-1 analogues are stable for 21-56 days once mixed 60/100

Weight management (154)

Supports weight loss 95/100· 82 srcAppetite suppression 85/100· 67 srcBMI reduction in obese adolescents 90/100· 15 srcBoosts blood flow to injuries 95/100· 7 srcAppetate regulation via increased fullness and reduced hunger and cravings 90/100· 5 srcAppetite reduction 72/100· 5 srcTreatment of obesity 90/100· 4 srcAppetite control 90/100· 3 srcFirst-line pharmacologic treatment for obesity in nonpregnant adults 90/100· 3 srcAppetate regulation and increased feelings of fullness 90/100· 3 srcImproves outcomes in Obesity-Related Heart Failure and Type 2 Diabetes 95/100· 2 srcHelps regulate blood sugar 95/100· 2 srcAppetite regulation 95/100· 2 srcFat Loss & Recomp 95/100· 2 srcAppetate regulation via increased feelings of fullness and reduced hunger/cravings 90/100· 2 srcAppetate regulation via increased fullness and reduced hunger 90/100· 2 srcFat Loss 95/100Modulates food preference 95/100Reduces food intake 95/100GLP-1 medicines for type 2 diabetes and obesity efficacy and safety 95/100Management and control of obesity 95/100Revolutionized obesity management 95/100Reduces visceral fat 95/100Increased feelings of fullness 95/100Boosts energy 95/100Appetite signaling reduction 95/100Improves symptoms, exercise capacity, and quality of life in patients with obesity and HFpEF 95/100GLP-1 receptor agonism 95/100Reduction in hunger and increased feelings of fullness 90/100Reduction in body mass index 90/100Reduction in fat mass 90/100Metabolic disease management 90/100Semaglutide and tirzepatide ranked as most effective first-line pharmacologic options for obesity 90/100Suppresses appetite and boosts feeling of fullness to regulate caloric intake 90/100First-line pharmacologic treatment for obesity in adults 90/100First oral GLP-1 agonist for obesity management 90/100Improvement in heart failure symptoms and exercise ability in obesity-related HFpEF 90/100Reduction in appetite and caloric intake 90/100Significant BMI reduction in obese adolescents 90/100Appetite regulation through increased fullness and reduced hunger 90/100BMI reduction in adolescents with obesity 90/100Reduction of BMI in obese adolescents 90/100Improves heart failure symptoms and 6-minute walk distance in obese HFpEF 90/100Reduction of heart-failure-related symptoms in obese patients 90/100Appetite regulation and prolonged satiety 90/100GLP-1 agonists reduce hunger and stomach emptying, leading to lower food intake 90/100Obesity Treatment 90/100Semaglutide approved for pediatric obesity management 90/100Zepbound FDA-approved for moderate-severe OSA in adults with obesity 90/100Treats type 2 diabetes, obesity, and some forms of heart disease 90/100Promotes satiety and reduces appetite 90/100Appetite suppression and reduced calorie intake 90/100Appetite suppression and reduction of 'food noise' 90/100Suppresses appetite 90/100Reduction in visceral adipose tissue 90/100FDA-Approved Treatment for Diabetes and Obesity 90/100Reduced craving for high-fat food 90/100Decreased appetite and food cravings 90/100Appetite suppression and satiety enhancement 90/100Adjunct to health behavior and lifestyle treatment 90/100Reduces hunger and increases feelings of fullness 90/100Slowed stomach emptying promoting earlier and prolonged satiety 88/100Satiety signaling 85/100Appetite suppression / Satiety signaling 85/100Reduced hunger and cravings 85/100Improvement in Binge Eating Disorder symptoms 85/100Preferentially reduces visceral fat 85/100Assessment of body composition 85/100Beneficial for adolescents with obesity over placebo 85/100Preoperative GLP-1 RA use does not diminish bariatric surgery effectiveness 85/100Additive appetite suppression via complementary satiety pathways 85/100GLP-1 receptor agonists reduce fat mass in adults with obesity 85/100Newer GLP-1 drugs like tirzepatide show better treatment persistence 85/100Reduction in waist circumference and waist-to-height ratio 85/100Improves symptoms in obesity-related heart failure with preserved ejection fraction 85/100Regulates appetite and helps reduce caloric intake by quieting food noise and hunger 85/100Reduces hunger and lowers food intake 85/100Semaglutide reduces asthma-related adverse outcomes in patients with comorbid asthma and obesity 85/100High-dose semaglutide is associated with preservation of kidney function in people living with obesity without diabetes 85/100Supports liver health 85/100Reduces hunger and stomach emptying leading to lower food intake 85/100Efficacy in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes 85/100Reduces hunger, cravings for high-fat foods, and calorie consumption 85/100Continuous semaglutide treatment prevents the rebound obesity and therapeutic resistance observed in cycling regimens 85/100Reduces hunger and stomach emptying 85/100Oral semaglutide 25 mg effective in obesity treatment targets and low-risk outcomes for cardiometabolic risk factors 85/100GLP-1 drugs suppress appetite and slow stomach emptying 85/100Reduced food cravings 85/100Reduced waist circumference and less body fat 85/100Supports brain health 85/100Reduction of 'food noise' 85/100Reduction in visceral fat 85/100Fat mobilization as a fuel source 85/100Reduced food cravings/reward signaling 85/100Reduces ectopic fat deposition 85/100Appetite suppression via neurological pathways 85/100Reduction in visceral fat mass 85/100Improved glycemic outcomes in Type 1 Diabetes with obesity 85/100Reduced hyperphagia 85/100Dual agonism provides stronger hunger suppression 85/100Attenuation of increases in total and visceral abdominal adiposity 80/100Treatment of disordered eating and feeding diseases 80/100Semaglutide shows promise in adolescents for obesity treatment 80/100Lowers desire for dairy, starchy, salty, spicy, and high-fat non-sweet foods 80/100Significant BMI reduction in migraine patients 75/10041% lower overall risk of developing obesity-related cancers 75/100Promotes satiety 72/100Attenuation of visceral abdominal adiposity and slowing of lean mass loss with hormone therapy 72/100Appetite and craving control 72/100Reduced hunger and food intake 72/100Treatment of obesity and diabetes 72/100Appetite suppression via GLP-1 receptor agonism 72/100Curb appetite 72/100Cost-effective access to GLP-1 receptor agonists during drug shortages via compounding 72/100Anti-obesity medications provide clinical benefit in conjunction with lifestyle interventions 72/100Significant fat mass reduction 72/100Substantial reductions in body mass index in older adults 72/100GLP-1 receptor agonists for obesity 72/100Cost reduction of ~50% with biosimilar GLP-1 medications 72/100Increases fullness and reduces appetite 72/100Alleviates food cravings 72/100Commercial validation of GLP-1 drugs at scale 72/100Reduces food cravings and 'food noise' 72/100Delays stomach emptying and increases satiety 72/100Regulates hunger hormones and reduces cravings 72/100GLP-1 has the strongest evidence base of any peptide therapy 72/100Dual GLP-1 and amylin targeting for obesity treatment 72/100Beneficial for obesity management 72/100GLP-1 receptor agonists work best as long-term medications 72/100Ozempic can treat obesity 72/100Metformin use associated with reduced dementia risk in patients under 65 with class I or II obesity 72/100Cost reduction of ~50% expected with biosimilar GLP-1 medications 72/100Helps you feel full faster and longer 72/100Appetite reduction and feeling of fullness 72/100Appetite suppression and improved eating control 72/100Increased Satiety 72/100Reduced appetite and cravings 70/100Increased feelings of satisfaction after eating 70/100Appetite suppression via reward pathway modulation 70/100Semaglutide mimics the natural GLP-1 hormone to reduce appetite and help you feel full longer 70/100Orforglipron showed promise in two Phase 3 trials as an oral GLP-1 agonist 70/100AstraZeneca's GLP-1 pill shows promise in obesity, diabetes trials 70/100Microdosing GLP-1 medications reduces adverse effects 70/100Reduces reward signals for sugary/fatty foods 70/100Appetite suppression via hypothalamic receptor activation 70/100Promotes feelings of fullness 70/100Reduced preference for high-fat and sugary foods 65/100Regulate appetite, metabolism, and body composition 65/100GLP-1 drug demand driving manufacturing expansion 60/100Treating obesity comprehensively improves related metabolic conditions 60/100Improved body composition 60/100Lipolysis stimulation 60/100Satiety signalling 60/100Reduced cravings / reduced 'food noise' 60/100

Cardiovascular & vascular (55)

Boosts blood flow to injuries 95/100· 24 srcPotential reduction in heart attacks and strokes 85/100· 18 srcPotential reduction in number of heart attacks and strokes 70/100· 5 srcReduced risk of nonfatal myocardial infarction 95/100· 2 srcReduced risk of worsening heart failure 90/100· 2 srcTreatment of Heart Failure 90/100· 2 srcBlood Pressure Reduction 80/100· 2 srcReduction in symptoms and physical limitations 95/100Reduces blood pressure via VSMC GLP-1 receptor 95/100Improvement of cardio-renal function 95/100Promotes natriuresis 95/100Reduction in Nonfatal Myocardial Infarction 95/100Improvements in cardiometabolic risk factors 95/100Supports liver health 95/100Anticoagulation for Stroke Prevention 95/100Reduces risk of serious heart attacks and strokes 95/100Significant improvement in heart failure symptoms and physical limitations 95/100Improves outcomes in heart failure with preserved ejection fraction 90/100Reduction of risk of heart attack and stroke 90/100Decreases in systolic blood pressure 90/100Reduces occurrence of serious health complications like heart attack and stroke 90/100Reduces occurrence of serious health complications 90/100Beneficial effects on blood pressure and lipid profile 90/100Superiority vs placebo for primary composite CV endpoint 90/100Cardioprotective actions of liraglutide via GLP-1R Tie2+ cells in experimental myocardial infarction 90/100Reduces risk of heart attack, stroke, and heart-related death in T2DM patients with heart disease 90/100Lowers rates of non-fatal heart attacks, non-fatal strokes, and heart failure hospitalizations 90/100Cardioprotective and renoprotective qualities 90/100Favorable effects on lipids and blood pressure 90/100Alirocumab approved to lower LDL-C in pediatric patients with HeFH 90/100Ozempic reduces CKD progression and CV death in adults 90/100Improvement in blood pressure and cholesterol 90/100Heart failure symptom improvement 90/100Improvement of blood vessel function 85/100Improved cardiometabolic measures 85/100Reduction in 3-point MACE 85/100Reduction in 3-point HF outcome 85/100Lowers blood pressure by approximately 5-7 mmHg 85/100Lowers blood pressure and cholesterol with long-term use 85/100Lowered heart disease risk 85/100Lower blood pressure and cholesterol levels 85/100Extended systemic exposure with ~155–184 hour half-life enabling sustained receptor activation 85/100Reduces risk of heart attack and stroke 85/100Improved lipid profiles 85/100Reduces triglycerides and LDL cholesterol 85/100LRP5 inhibition reduces platelet activation and thrombus formation with lower bleeding risk than aspirin or clopidogrel 80/100Improved Cholesterol Profile 80/100Reduction in systolic and diastolic blood pressure 72/100Aficamten improves heart health in obstructive HCM 72/100Improved blood pressure 72/100Improved lipids 72/100Speeds recovery 70/100BMI reduction of at least 15% lowers heart failure risk by 32% 70/100Deramiocel improves upper limb function and cardiac pumping in Duchenne 70/100GLP-1 agonists may protect the heart after a heart attack 65/100

Renal & hepatic (43)

Improved kidney outcomes 95/100· 2 srcReduces risk of major kidney events by 24% 95/100· 2 srcSupports liver health 90/100· 2 srcTreatment of Kidney Disease 90/100· 2 srcIncreases glomerular filtration rate and natriuresis 95/100Slows eGFR decline and progression of chronic kidney disease 95/100Increases glomerular filtration rate 95/100Promotes natriuresis 95/100Reduces albuminuria and slows eGFR decline in T2D 95/100Reduces kidney failure by 16% and major heart events by 13% across GLP-1 drugs 95/100Reduces major kidney outcomes by 24% in T2D and CKD 95/100Increases glomerular filtration rate and promotes natriuresis via VSMC GLP-1R 95/100Reduced risk of major kidney disease events 95/100Attenuates progression of chronic kidney disease and slows eGFR decline 90/100Slows progression of kidney disease 90/100Reduced risk of kidney disease progression 90/100NASH resolution 90/100Lowers risk of kidney disease worsening, kidney failure, and death in adults with T2DM and CKD 90/100Slows progression of chronic kidney disease 90/100Renoprotective effects delaying chronic kidney disease progression 90/10024% reduction in composite kidney outcome including kidney failure and sustained eGFR decline 90/100Kidney Disease Protection 90/100Improvement in NAFLD/MASLD 90/100Reduction of elevated ALT and AST levels 90/100Kidney protection 90/100Reduced risk of kidney stone growth 90/100Prevention of heart failure and progression of kidney disease 90/100MASH treatment 90/100Chronic kidney disease management 90/100Lower risk of hepatic complications 88/100Kidney disease risk reduction 85/100Reduces protein leakage into urine 85/100Improvement of hepatocyte ballooning 85/100Reduces kidney decline in adults with T2D and chronic kidney disease 85/100Improves vasculature and kidney health 85/100Hepatic Steatosis Reduction 85/100Consistent GLP-1 use produces protective effects preventing heart attacks and kidney disease progression 80/100BMI reduction of at least 15% lowers chronic kidney disease risk by 30% 80/100Treatment of kidney disorders 72/100Protects the heart and kidneys 72/100Improved kidney outcomes in chronic kidney disease 72/100MASH resolution 72/100Tolerable in patients with NASH 60/100

Gastrointestinal & gut (41)

Heals gut issues 95/100· 10 srcInduces vasorelaxation in preconstricted mesenteric arteries 95/100· 2 srcInduces vasorelaxation in mesenteric arteries 95/100Induces vasorelaxation in pre-constricted mesenteric arteries 95/100Supports brain health 95/100Reduces inflammation 90/100Helps regulate blood sugar 90/100Minimizes gastrointestinal side effects via gradual 5-step titration over 16 weeks 90/100Delays the time it takes for food to empty out of the stomach 90/100Intestinal growth and absorption 90/100Semaglutide induces direct vasorelaxation in preconstricted mesenteric arteries ex vivo 88/100Celiac Symptom Reduction 85/100Reduced nausea 85/100Reduces hunger and slows stomach emptying 85/100Constipation relief 85/100Diarrhea management 85/100Psyllium husk improves stool consistency 85/100Prebiotic fiber increases endogenous GLP-1 secretion 85/100Supports weight loss 85/100Appetite Suppression 85/100Digestive support with Probiotics 85/100Dietary fibers can boost endogenous GLP-1 secretion modestly 85/100Oral bioavailability of GLP-1 agonist via enteric coating 80/100High-throughput tissue screening identifies novel excipient combinations yielding up to 60% intraduodenal bioavailability for vancomycin 80/100Associated with lower fracture risk compared to sleeve gastrectomy in obesity 80/100Reduction of gas and bloating 80/100Improved stool consistency via Probiotics 80/100Lower risk of gastrointestinal adverse events compared to orforglipron 75/100Constipation relief via Magnesium 75/100Facilitates stomach absorption of peptides 72/100Enhanced permeation across intestinal epithelium 72/100Reduces appetite and slows digestion 72/100Activates hypothalamic satiety centers for central appetite regulation 72/100Fiber supplementation manages constipation 72/100Reduction of nausea 72/100Fiber helps with constipation 72/100Fiber eases constipation 72/100Oral small molecule GLP-1 drugs have the potential for better dose titration to help control gastrointestinal side-effects of injectable peptides 70/100GEP44 reduces food intake and increases calorie expenditure without characteristic GLP-1 agonist gastrointestinal side effects in preclinical models 70/100Higher bioavailability than oral tablets 70/100Microdosing may reduce the risk or severity of gastrointestinal side effects 65/100

Neuroprotection & cognitive (41)

Improvement of Alzheimer’s disease-related biomarkers 75/100· 2 srcGLP-1RAs inhibit the initiation of toxic amyloid-beta 42 aggregation 95/100Improvement in taste sensitivity 90/100Reduced risk of developing substance use disorders 88/100Fewer overdoses and drug-related deaths in patients with existing addiction 88/100Decreased emergency department visits and hospitalizations for addiction 88/100Reduced injection pain with high sodium chloride and low phenol formulation 85/100Observational data links GLP-1RA use to lower rates of all-cause dementia 85/100Reduces drinking in alcohol use disorder 85/100Reduction in alcohol consumption 85/100Reduction in alcohol cravings 85/100Reduced odds of binge drinking 85/100Attenuation of stimulating and sedative effects of alcohol 85/100GIP acts as a natural hunger suppressant via AgRP neurons 85/100Potential role of GLP-1 receptor agonists in multiple sclerosis 80/100Supports brain health 80/100Lowers rates of opioid overdose and alcohol intoxication 80/100Reduced risk of dementia 75/100Neuroprotection 75/100decrease risk of developing dementia 75/100act on a shared biological pathway to blunt the craving itself 75/100Potential disease-modifying effects for neurodegenerative disorders 75/100Improvements in mood and quality of life 75/100Reduced interest in alcohol 75/100Improvement in Alzheimer's biomarkers 75/100Reduced risk of developing new substance use disorders 72/100Troriluzole shows efficacy in spinocerebellar ataxia 72/100Improvement of Alzheimer's-related biomarkers 72/100Slower progression of Alzheimer's disease 72/100Improved memory function 70/100Reduced phospho-tau accumulation 70/100Less treatment escalation compared to topiramate 70/100Potential aid in addiction treatment 70/100Reduces depression and anxiety scores 70/1005-HTP serves as a precursor to the neurotransmitter serotonin 70/100Neuroprotective effects 70/100Delay in onset and progression of Parkinson's disease 65/100Neuroprotection in Multiple sclerosis models 65/100lower depression and anxiety risk 60/100GLP-1 drugs may reduce addiction behaviors 60/100Reduced Cravings 60/100

Musculoskeletal (20)

Boosts blood flow to injuries 95/100Speeds muscle recovery 95/100Treatment of Postmenopausal Osteoporosis 90/100Rheumatoid Arthritis Treatment 90/100Supports weight loss 85/100Reduced total testosterone 85/100Significant increase in total and free testosterone levels 85/100Reversal of low testosterone in men with obesity or type 2 diabetes 85/100Supports bone healing 82/100BMI reduction of at least 15% lowers osteoarthritis risk by 37% 80/100Reduction of total testosterone and DHEAS 80/100Fracture-risk benefits 75/100Testosterone / TRT is a well-established hormone replacement with decades of clinical data 72/100Apitegromab improves motor function in spinal muscular atrophy 72/100Improvement in Rheumatoid Arthritis symptoms and disease activity 72/100Knee osteoarthritis pain reduction 72/100Improvement in male testosterone levels and sperm quality in obesity 70/100Repairs tendons and ligaments 70/100Allosteric binding site targeting may lead to drugs with fewer off-target side-effects 65/100Joint pain reduction 60/100

Reproductive & hormonal (15)

Statistically significant improvement in sexual desire for HSDD in women 90/100FDA-Approved Treatment for HSDD in Premenopausal Women 90/100Treatment of hypoactive sexual desire disorder 90/100PTH replacement for calcium and phosphate homeostasis in chronic hypoparathyroidism 85/100Normalization of menstrual cycles in PCOS 85/100Menstrual cycle normalization in PCOS 85/100Treatment of polycystic ovary syndrome 80/100Restoration of ovulation 80/100Improvement in men's reproductive health 80/100Improvement in female fertility-related outcomes in PMOS 75/100Sustained GH elevation with favorable safety profile in early trials 75/100GH Secretagogues stimulate pituitary GH release 72/100Growth Hormone receptor agonism via recombinant hGH and synthetic GH fragments 72/100Preservation of male reproductive function without suppressing spermatogenesis 70/100Boosts energy 65/100

Performance & recovery (13)

Improvement in exercise function 95/100Improved exercise tolerance 95/100Improvement in exercise capacity and symptoms in heart failure patients 90/100Effective stimulation of endogenous GH secretion for pediatric growth hormone deficiency 90/100Endurance Increase 85/100Highly specific and biologically potent therapeutic profile 85/100Growth hormone restoration 85/100Increased hand grip strength 80/100Growth hormone secretion 75/100Improved adherence and treatment access due to oral formulation 72/100Improved symptoms, physical limitations, and exercise function in HFpEF 72/100Reduced health care utilization compared to topiramate 70/100Speeds recovery 70/100

Antimicrobial & antiviral (13)

Supports liver health 90/100Histological resolution of NASH 90/100Significant reduction in visceral adipose tissue in HIV-associated lipodystrophy 90/100Treats metabolic dysfunction-associated steatohepatitis 90/100Treats noncirrhotic metabolic dysfunction-associated steatohepatitis 90/100Resolution of NASH 90/100Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis 90/100Treatment for metabolic-associated steatohepatitis 85/100Improvement in histologic steatohepatitis and fibrosis in MASH 85/100Survodutide improves metabolic dysfunction-associated steatohepatitis 80/100Treatment of NASH 75/100Potential treatment for metabolic-associated steatohepatitis 72/100Bacteriostatic water inhibits bacterial growth for multi-dose use 72/100

Cancer / tumor (13)

Oncology Treatment 90/100Xiaojin Pills regulates metabolites to treat lung cancer 85/100Useful across multiple medical disciplines including endocrinology, metabolism, and oncology 85/100GLP-1 agonists associated with ~30% lower breast cancer incidence 82/100Lowers overall cancer risk 80/100Approximately 30% lower breast cancer risk observed in women 75/10058% lower risk of endometrial cancer 75/10050% or greater risk reduction in multiple myeloma, pancreatic cancer, and colorectal cancer 75/100Amivantamab + chemotherapy reduces risk of disease progression in NSCLC 72/100Blenrep outperforms standard myeloma therapies in progression measures 72/100Hinting at reduced cancer incidence in patients with metabolic risks 72/100TRT associated with lower prostate cancer risk when not using concomitant aromatase inhibitors 72/100GLP-1 agonists may extend lives of colon cancer patients 65/100

Tissue & wound healing (10)

No increased risk of ocular disorders compared to other antidiabetics 95/100Supports liver health 90/100Repairs tendons and ligaments 85/100Boosts collagen production 85/100Boosts blood flow to injuries 70/100Reduces inflammation 70/100Potential protection against the development of diabetic retinopathy and age-related ocular diseases 70/100Capsiate mimics capsaicin's effects like boosting metabolism and fat burning without the spicy heat 70/100Enzymatic Protection via Cyclization 65/100Lyophilized peptides are stable for weeks at room temperature 60/100

Anti-inflammatory (9)

Reduces inflammation 95/100· 2 srcReduction of C-reactive protein 95/100Reduces C-reactive protein inflammatory marker 95/100Pronounced reduction of C-reactive protein inflammatory marker 95/100Reduction in C-reactive protein inflammatory marker: 39% reduction with semaglutide vs 3% with placebo 88/100Qingre Tonglin capsules inhibit inflammasome formation and reduce pyroptosis in CNP 85/100Suppression of pro-inflammatory cytokines 80/100Decrease epigenetic age 75/100Donidalorsen prevents swelling attacks in hereditary angioedema 72/100

Anti-aging & longevity (9)

Decrease epigenetic age 85/100· 2 srcReduced death from any cause 95/100Reduces risk of premature death from any cause 88/100Associated with lower all-cause mortality risk 85/100Decrease pace of aging 85/100Improvement in Health-Related Quality of Life 85/100Decreased epigenetic age via diverse interventions 85/100Reduce all-cause mortality risk 80/100GLP-1 agonists may potentially slow down the ageing process 60/100

Skin, hair & cosmetic (8)

Hair shedding occurs in ~3% of Wegovy users 90/100Treatment of moderate to severe atopic dermatitis 85/100Stiffness improvement 85/100Speeds recovery 80/100Improves skin health 75/100Xeligekimab blocks IL-17A to treat plaque psoriasis 72/100Sexual Function peptides utilize central melanocortin and hypothalamic pathways for libido and sexual response 72/100Improvement in Psoriasis severity scores 70/100

Cytoprotection / cellular defense (5)

Reduction in Serious Adverse Events 90/100Prevention of potential overdose issues associated with subcutaneous injections 85/100Improved physical and chemical stability of GLP-1 peptides in liquid compositions 85/100Expansion of accessible target space via targeted protein degradation 72/100Endotoxin testing is critical for safety 60/100

Energy & mitochondrial (4)

Boosts energy 95/100Improved mitochondrial efficiency 85/100NAD+ / NMN has promising preclinical data with emerging human trial evidence 72/100Mitochondrial signaling and metabolic stress resilience 70/100

Immune modulation (4)

Strengthens immunity 85/100Enhancement of regulatory T-cell function 75/100Crovalimab provides rapid and sustained inhibition of complement pathway for PNH 72/100Sibeprenlimab targets immunological drivers of IgA nephropathy 72/100

Anti-fibrotic (3)

Treatment of noncirrhotic MASH with fibrosis 90/100Supports liver health 90/100Semaglutide induces MASH resolution without worsening of fibrosis 90/100

Other Benefits (19)

Reduced all-cause mortality 95/100· 2 srcSignificant body fat reduction 72/100· 2 srcImproves sleep 90/100· 2 srcVSMC GLP-1R is required for semaglutide-induced increase in glomerular filtration rate and natriuresis 90/100Improved patient quality of life 90/100Updated NICE guidance could prevent up to 17,000 deaths over three years across the UK 90/100Slows stomach emptying 90/100Systolic Blood Pressure Reduction 90/100Optimized therapeutic efficacy 85/100Suppression of Addiction 85/100Slowing of arterial plaque buildup 80/100Semaglutide reduces multi-organ proteomic-based biological age across cohorts 80/100Lower risk of discontinuation due to adverse events compared to orforglipron 75/100Weakened link between impulsivity and violent behavior 75/100Reduction of epigenetic age in humans 75/100Tolebrutinib shows efficacy in non-relapsing secondary progressive MS 72/100Weakened link between alcohol use and violent behavior 65/100Reduction of 'food noise' 60/100Reduction of oxidative stress 95/100

How People Use It

Under the skin

  • 2.4 mg — Chronic weight management (BMI >=30, or >=27 with comorbidity)
  • 0.25 mg once weekly for the first 4 weeks, then increase to 0.5 mg once weekly. If blood glucose levels are still too high, dose may continue to increase every 4 weeks until reaching the effective amount (up to 2 mg once weekly).

For research purposes only. Not medical advice. Talk to a doctor before use.

Get Semaglutide for Your Research

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Find Semaglutide Research Suppliers
Tested purity COA available Fast shipping
Technical Details & Research (click to expand)

Mechanism of Action

A long-acting GLP-1 receptor agonist. Mimics human glucagon-like peptide-1 to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Approved as Ozempic (type 2 diabetes) and Wegovy (chronic weight management). Semisynthetic GLP-1 analog with a C18 fatty-acid side chain enabling albumin binding and extended half-life.

Known Side Effects

All Dosing Protocols

Wegovy chronic weight management (FDA-approved) — SubQ · 2.4 mg 92/100
GLP-1 RAs — SubQ 95/100

Research Citations (533)

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    RCT2021 Key study 95/100
    Source

  • Two-Year Effects of Semaglutide (STEP 5)

    RCT2022 92/100
    Source

  • Once-Weekly Semaglutide for Weight Management: A Clinical Review

    Review2022 82/100
    Source

  • STEP 1 - Semaglutide in Overweight/Obesity

    Registry2018 88/100
    Source

  • Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

    2019 95/100
    Source

  • Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

    2018 95/100
    Source

  • Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial

    2019 95/100
    Source

  • Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

    2019 95/100
    Source

  • Semaglutide and transcriptional regulation of WAT to BAT conversion and BAT activation

    90/100
    Source

  • Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

    2023 95/100
    Source

  • Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

    2024 95/100
    Source

  • Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR)

    2025 95/100
    Source

  • Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    2023 95/100
    Source

  • Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

    2024 95/100
    Source

  • Pharmacological management of obesity and metabolic and bariatric surgery: clinical implications

    90/100
    Source

History & Milestones

Key moments in Semaglutide’s research and regulatory timeline — sourced and dated.

  1. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisPublicationJan 1, 2026
    95/100↗ source
  2. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR)PublicationJan 1, 2025
    95/100↗ source
  3. Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressurePublicationJan 1, 2025
    90/100↗ source
  4. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trialPublicationJan 1, 2025
    95/100↗ source
  5. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DiabetesPublicationJan 1, 2024
    95/100↗ source
  6. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialPublicationJan 1, 2024
    95/100↗ source
  7. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and ObesityPublicationJan 1, 2023
    95/100↗ source
  8. Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesPublicationJan 1, 2023
    95/100↗ source
  9. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host DiseasePublicationJan 1, 2020
    95/100↗ source
  10. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 TrialPublicationJan 1, 2019
    95/100↗ source
  11. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical TrialPublicationJan 1, 2019
    95/100↗ source
  12. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled TrialPublicationJan 1, 2018
    95/100↗ source

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, dosing at a glance, and what the research says — one page, one email.

No spam. Unsubscribe anytime.

Related on The Health Stacks

Explore by goal

GLP-1 & Metabolic Peptides

Related peptides

TirzepatideRetatrutideMOTS-c

Compare

Semaglutide vs Tirzepatide Semaglutide vs Retatrutide